| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| October 3, 2019 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,000 | -- | 130,118 | |
| May 6, 2013 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 130,000 | |
| October 3, 2019 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,000 | -- | 129,880 | |
| October 3, 2019 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,000 | -- | 129,737 | |
| December 22, 2003 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 18,349 | -- | 128,346 | |
| June 16, 2016 | Director, Chairman, President and CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 7,500 | $1.35 | 128,021 | |
| May 13, 2024 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 112,500 | -- | 126,666 | |
| May 7, 2010 | President & CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 4,000 | $3.95 | 126,662 | |
| February 11, 2014 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 125,500 | |
| May 15, 2018 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 124,643 | |
| October 3, 2019 | Controller | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,000 | -- | 124,557 | |
| January 19, 2009 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,667 | $2.72 | 123,246 | |
| September 6, 2016 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,332 | -- | 122,663 | |
| January 19, 2008 | Chief Executive Officer | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 33,333 | -- | 122,662 | |
| November 19, 2008 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,100 | $2.70 | 122,562 | |
| October 15, 2012 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 2,500 | $2.36 | 122,042 | |
| January 19, 2009 | VP & Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 11,667 | $2.72 | 121,667 | |
| March 15, 2024 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 120,950 | |
| February 19, 2016 | Director, CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 3,000 | $1.27 | 120,521 | |
| November 17, 2008 | Director | Form 4 | Open market or private purchase of non-derivative or derivative security | 7,000 | $2.76 | 120,462 | |
| January 19, 2009 | Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 6,666 | $2.72 | 120,000 | |
| May 14, 2019 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,000 | -- | 119,689 | |
| October 15, 2012 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 34,542 | $2.77 | 119,542 | |
| February 2, 2016 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 118,886 | |
| February 17, 2016 | Director, CEO | Form 4 | Open market or private purchase of non-derivative or derivative security | 2,000 | $1.27 | 117,521 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
